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Abstract. Given the prognostic significance of pathological
complete response (pCR) to neoadjuvant chemotherapy,
we sought to chronicle the clinical course of breast cancer
patients whose tumors exhibited pCR at our institution. We
retrospectively reviewed 5,533 cancer center patients treated
for a first primary breast cancer between March, 1999 and
September, 2010 to identify those who received neoadjuvant
chemotherapy that resulted in pCR (i.e., no residual invasive
malignancy in the breast or axilla). The descriptive statistics of
treatments received, recurrence, morbidity and mortality as of
October, 2013 were reported. Of the 5,533 patients reviewed,
86 met the inclusion criteria. The mean age at diagnosis was
48 years [standard deviation (SD), 9.4 years] and the mean length
of follow‑up was 68 months (SD, 27 months). The majority of
the patients underwent axillary lymph node dissection (ALND;
n=60, 69.8%), received adjuvant radiation therapy (XRT;
n=72, 83.7%), had poorly differentiated (grade 3) tumors (n=74,
86.1%) and had pure ductal histology (n=74, 86.1%). A total of
5 patients (5.8%) developed disease recurrence. All the patients
who recurred had grade 3 tumors with ductal histology and
underwent ALND for known pre‑neoadjuvant‑treatment lymph
node metastases; none received adjuvant chemotherapy. A total
of 4 patients (4.7%) succumbed to the disease, 3 due to breast
cancer recurrence <18 months following the initial diagnosis.
Recurrence following pCR was rare, but when it did occur,
time‑ to‑recurrence was short at <18 months. All the patients
who recurred and eventually succumbed to breast cancer
had axillary metastases at diagnosis, indicating that axillary

disease is a major negative prognostic factor in patients who
achieve pCR following neoadjuvant chemotherapy.
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Patient selection. Clinical, demographic and pathological data
from all the breast cancer patients treated at our institution are
prospectively recorded in a database. In a retrospective review
of this database, 5,533 patients treated for a first primary
breast cancer at Siteman Cancer Center between March, 1999
and September, 2010 were identified. Subsequently, patients
who received neoadjuvant chemotherapy for treatment of a
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Introduction
As our knowledge of the human genome and the molecular
subtypes of particular cancers increases, the field of breast
oncology is becoming increasingly focused on individualizing
treatment based on the clinical and biochemical profile of a
given patient. Nomograms are being developed and used to
guide the type and extent of therapy patients receive, with the
hope that we optimally treat many and overtreat few (1,2).
As we collectively navigate the path from clinical assessment to individualized treatment to optimized outcome, the
significance of proximal clinical endpoints must not be underestimated, as they assist clinicians in determining whether to
proceed with or modify a given patient's treatment course and
may also facilitate pharmaceutical development by providing
a surrogate endpoint of efficacy that does not mandate the long
follow‑up periods required to evaluate differences in survival
or recurrence (3,4).
Pathological complete response (pCR) to neoadjuvant
chemotherapy has emerged as a reliable prognostic indicator
for overall and event‑free survival following breast cancer diagnosis (5‑10), occurring in ~15‑40% of breast cancer patients
receiving neoadjuvant chemotherapy (3). Given the prognostic
significance of pCR and the evolution of decision‑making
nomograms for the management of breast cancer, we aimed
to chronicle the clinical course of breast cancer patients at
our institution (Siteman Cancer Center, St. Louis, MO, USA)
whose index tumors exhibited pCR.
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Table I. Characteristics of breast cancer patients (n=86) exhibiting pCR following neoadjuvant chemotherapy.a
Clinical characteristics
Age, years [median (range)]

Follow‑up, months [median (range)]
Race, n (%)
African American
Asian American
Caucasian
Bilaterality, n (%)
Bilateral
Unilateral

Lymph node involvement, n (%)
Yes
No
TNM stage, n (%)
Early (I‑IIA)
Late (IIB‑IIIC)

Receptor status, n (%)
ER
Positive
Negative
PR
Positive
Negative
HER2/neu
Positive
Negative
ER‑/PR‑/HER2+
ER‑/PR‑/HER2‑ (triple‑negative)
Tumor grade, n (%)
1
2
3
Histology, n (%)
Ductal only
Lobular only
Other

Values
48 (27‑70)

39 (8‑124)
25 (29.1)
1 (1.2)
60 (69.7)
2 (2.3)
84 (97.7)
49 (57.0)
37 (43.0)
38 (44.2)
48 (55.8)

25 (29.1)
61 (70.9)
17 (19.8)
69 (80.2)
31 (36.0)
55 (64.0)
16 (18.6)
43 (50.0)
2 (2.3)
10 (11.6)
74 (86.1)
74 (86.1)
2 (2.3)
10 (11.6)

Siteman Cancer Center (March, 1999‑September, 2010). pCR, pathological complete response; ER, estrogen receptor; PR, progesterone
receptor; HER2, human epidermal growth factor receptor 2.
a

pathologically confirmed invasive (stages I‑III) breast cancer
were identified and their medical records were reviewed to
determine which of these tumors exhibited pCR, defined as no
evidence of residual invasive malignancy in the breast or axilla.
As ductal carcinoma in situ (DCIS) generally does not regress
with chemotherapy and evidence of its effect on prognosis is

equivocal (11,12), patients with only residual DCIS following
neoadjuvant chemotherapy were included in the pCR cohort.
Institutional Review Board approval was obtained prior to
the commencement of this retrospective study at Washington
University School of Medicine. Written consent from the
patients was not required, due to the retrospective nature of
this study.
Statistical analysis. The descriptive statistics of treatments received, recurrence, morbidity and mortality as of
October, 2013 are reported. All the statistical analyses were
conducted using SAS 9.3 software (SAS Institute Inc., Cary,
NC, USA).
Results
Patient characteristics. Of the 5,533 patients reviewed,
746 received neoadjuvant chemotherapy and 86 (1.6% of all
patients, 11.5% of neoadjuvant chemotherapy recipients) met
the inclusion criteria (Table I). The mean age at diagnosis was
48 years [standard deviation (SD), 9.4 years] and the mean
length of follow‑up was 68 months (SD, 27 months). The
majority of the patients underwent axillary lymph node dissection (ALND; n=60, 69.8%), were Caucasian (n=60, 69.7%),
received adjuvant radiation therapy (XRT; n=72, 83.7%), had
poorly differentiated (grade 3) tumors (n=74, 86.1%), had only
ductal histology (n=74, 86.1%) and received a taxane as part of
their neoadjuvant treatment (n=83, 96.5%). Due to inconsistencies in the information documentation process in our database,
the administration of anti‑human epidermal growth factor
receptor 2 (HER2)/neu treatments could not be determined for
all patients and, accordingly, summary statistics on this treatment variable were not provided.
Outcome. A total of 5 patients (5.8%) developed disease
recurrence (1 locoregional and distant and 4 distant recurrence) (Table II). The only patient in our cohort with residual
DCIS developed recurrence. All the patients who recurred had
grade 3 tumors with ductal histology and underwent ALND
for known pre‑neoadjuvant treatment lymph node metastases;
none of the patients with recurrence received adjuvant chemotherapy. A total of 4 patients (4.7%) succumbed to the disease,
3 due to breast cancer recurrence <18 months after the initial
diagnosis and 1 due to metastatic small bowel adenocarcinoma.
Discussion
High tumor grade and the presence of lymph node metastases
at diagnosis were two prominent clinical characteristics shared
by all patients who recurred following pCR. High tumor grade
has been previously reported as a marker of pCR probability,
as the high mitotic activity of poorly differentiated tumors
appears to render them more susceptible to the cytotoxic
effects of standard chemotherapy regimens (13,14). However,
this potential vulnerability to chemotherapy lies in tension
with the fact that high tumor grade has, outside the context
of pCR, been demonstrated to be a predictor of breast cancer
progression, recurrence and death (15). This paradox points to
a greater challenge in therapeutic decision‑making for breast
cancer patients: Specifically, when trying to determine who is
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Table II. Recurrence following pCR.a
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most likely to experience pCR, one needs to consider not
only the patients with enhanced susceptibility to neoadjuvant
therapies, but also the patients who are most likely to benefit
from these treatments. Patients with grade 3 tumors are at
the intersection of these two idealized populations: they are
more likely to have poor outcomes as a result of their disease,
but they are also more likely to respond to chemotherapeutic
treatment. Neoadjuvant chemotherapy is generally reserved
for patients with locally advanced disease (a number of
whom have tumor biology that precludes systemic endocrine
therapy) in order to treat disseminated disease and facilitate
breast conservation therapy (16). However, a recent study
demonstrating the safety of neoadjuvant systemic therapy in
early‑stage patients (17) should mitigate concerns regarding the
administration of preoperative systemic therapy to early‑stage
patients with poorly differentiated tumors, but displaying
other disease characteristics that may otherwise have encouraged oncologists to forego chemotherapy. Thus, administering
neoadjuvant chemotherapy to grade 3 patients of all stages may
significantly affect the rate of pCR and concomitant outcomes,
although additional clinical trials investigating the efficacy of
neoadjuvant chemotherapy in early‑stage patients are required.
In addition, there is increasing evidence that a certain
subset of women with axillary disease at diagnosis require
adjuvant systemic therapy, regardless of their local response
to neoadjuvant treatment, as demonstrated on operative
pathology (18). In our cohort, a total of 5 patients recurred, 3 of
whom did so within 18 months of definitive surgical treatment;
none of these 5 patients received adjuvant chemotherapy. Such
a short interval between diagnosis and post‑treatment recurrence likely reflects the failure of neoadjuvant treatment in
these patients and is further proof that axillary lymph node
metastases should be considered as markers of disseminated
disease that may continue to progress regardless of pCR in the
breast and axilla. In addition, all 5 patients with recurrence
were aged <50 years at diagnosis, young age being a clinical
characteristic that compounds the negative prognosticators of
high grade and axillary disease at diagnosis.
Finally, recent studies have demonstrated the extent to which
the prognostic accuracy of pCR depends on a given tumor's
molecular subtype. Specifically, in a large meta‑analysis
including 7 German randomized trials, von Minckowitz et al
found that pCR appeared to be a reasonable surrogate
endpoint for patients with luminal B/HER2‑, ER‑/PR‑/HER2+
and triple‑negative biomarker profiles, but not for those
with luminal B/HER2+ or luminal A tumors (12). However,
of the 5 patients in our cohort who developed recurrence
following pCR, 2 had ER‑/PR‑/HER2+ disease (1 succumbed
to the disease and 1 remains alive and disease‑free) and 2 had
triple‑negative disease, both of whom succumbed to their
cancer. Thus, even for the subset of patients for whom pCR is
a good prognosticator, its accuracy is not 100%.
Major advances have been made over the past 15 years
in refining the potential use of pCR with regards to medical
decision‑making for patients with breast cancer. For example,
it was observed that, although tumors with estrogen and/or
progesterone receptors are less likely to undergo pCR following
neoadjuvant systemic therapy, patients with these tumors tend
to have better long‑term outcomes compared with patients
with hormone receptor‑negative disease (14,16). Furthermore,

pCR does not appear to be a useful predictor of outcome for
assessing the long‑term efficacy of neoadjuvant endocrine
therapy, which rarely results in pCR (19). As described above,
we are developing a better sense of the optimal way to interpret and utilize pCR in patients with tumor subtypes for whom
pCR has been associated with improved outcomes. The next
rational step in prognostication with pCR would be to further
delineate which particular molecular subtypes among those
predisposed to pCR are more likely to recur following pCR
and the underlying mechanisms. Notably, the only patient
in our cohort who had residual DCIS following neoadjuvant
chemotherapy (as allowed for in our inclusion criteria) developed a recurrence. As proposed in a recent study, the standard
definition of pCR, in which residual in situ malignancy is
allowed to be present, may require revision (12). DCIS may
actually have a greater malignant potential than once thought
in certain tumor subtypes; in addition, its close proximity to
overlooked invasive disease may be of greater significance
than previously appreciated (12). None of the patients who
recurred received adjuvant therapy, although some may have
had both known and unknown clinicopathological characteristics, such as residual DCIS, which may have prompted further
treatment had their tumors not shown pCR. For a subset of
breast cancer patients who receive neoadjuvant chemotherapy,
pCR may confer a false sense of confidence that diverts them
and their oncologists away from the systemic adjuvant treatment that may have otherwise prevented recurrence or even
saved their lives.
Our findings corroborate previous research demonstrating
that, while pCR portends promising outcomes for the majority
of neoadjuvant chemotherapy recipients with breast cancer,
it holds significantly less prognostic significance for certain
women, specifically those whose disease lies at the intersection of multiple negative prognosticators, including high grade,
preoperative axillary metastases, young age and aggressive
tumor biology.
Additional prospective studies are warranted to determine which clinicopathological characteristics mitigate the
prognostic efficacy of pCR as a predictor of disease‑free and
overall survival among subtypes (namely, ER‑/PR‑/HER2+
and triple‑negative) whose receptor statuses usually lend
themselves to accurate prognostication by pCR. Such research
would undoubtedly help with the refinement of treatment
decision nomograms in women undergoing neoadjuvant
chemotherapy.
Our study's findings are important for a number of reasons.
First, to the best of our knowledge, the average length of
follow‑up for our cohort (68 months) is the longest in the
literature on pCR in breast cancer, allowing us to demonstrate
the relative long‑term infrequency of recurrence following
pCR, while showing that, when recurrence does occur, it
may happen quite soon following pathological confirmation
of response. Second, while our study identified characteristics (such as young age and the presence of axillary disease)
that were found to be associated with post‑pCR recurrence in
other larger cohorts (20,21) by drilling down on the pretreatment characteristics, received therapies and post‑therapeutic
course of our patients who recurred following pCR, we have
identified additional factors (including tumor grade, the presence of residual DCIS and non‑administration of adjuvant
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chemotherapy) that may warrant additional investigation, both
in isolation and in association with each other.
Our study was limited first and foremost by the retrospective
nature of our review. Women who receive neoadjuvant chemotherapy are more likely to have hormone receptor‑negative,
biologically aggressive tumors, for which the availability of
alternative treatments is more limited. Accordingly, there is
significant selection bias in our sample, which was also insufficient for comparative statistical analysis; we chose not to
compare the 86 patients who underwent pCR to the 660 who did
not, as we were concerned that uncontrolled differences between
these groups would significantly confound attempts at statistical
comparison. Second, all the patients in our study were treated at
a high‑volume NCI‑designated Comprehensive Cancer Center,
although the majority of the patients in this country obtain their
chemotherapy from non‑academic, community medical oncologists; thus, the extent to which our patients achieve pCR and the
reasons why they do so may not reflect the treatment experience
of the typical breast cancer patient.
In conclusion, first primary breast cancer patients whose
tumors exhibited pCR following neoadjuvant chemotherapy
had low rates of breast cancer‑specific mortality and recurrence compared to the general population of breast cancer
patients of similar stage, although when recurrence did occur,
the time‑to‑recurrence was often short at <18 months. All the
patients who recurred and eventually succumbed to breast
cancer had poorly differentiated tumors with axillary metastases at initial diagnosis, indicating that axillary lymph node
disease burden may itself be a negative prognostic factor in
patients with a first primary breast cancer who achieve pCR
following neoadjuvant chemotherapy.
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